TD Asset Management Inc Grows Position in Insulet Corporation $PODD

TD Asset Management Inc grew its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 15.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,753 shares of the medical instruments supplier's stock after purchasing an additional 3,765 shares during the quarter. TD Asset Management Inc's holdings in Insulet were worth $9,034,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the period. American Century Companies Inc. lifted its stake in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after acquiring an additional 297,734 shares during the period. Groupama Asset Managment lifted its stake in Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after acquiring an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Insulet by 4.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after acquiring an additional 27,408 shares during the period. Finally, Federated Hermes Inc. lifted its stake in Insulet by 23.4% in the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier's stock worth $166,198,000 after acquiring an additional 120,197 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on PODD shares. Rothschild & Co Redburn raised their price target on Insulet from $350.00 to $370.00 and gave the stock a "buy" rating in a research note on Friday, October 3rd. JPMorgan Chase & Co. raised their price target on Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research note on Friday, September 12th. Royal Bank Of Canada raised their price target on Insulet from $350.00 to $365.00 and gave the stock an "outperform" rating in a research note on Friday, October 10th. Morgan Stanley reaffirmed an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group increased their price objective on Insulet from $353.00 to $399.00 and gave the stock a "buy" rating in a report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $348.05.

Insider Transactions at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Price Performance

PODD opened at $318.59 on Monday. The stock has a 50-day moving average price of $326.22 and a 200-day moving average price of $302.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a market cap of $22.43 billion, a PE ratio of 96.84, a P/E/G ratio of 2.66 and a beta of 1.40. Insulet Corporation has a 1 year low of $226.50 and a 1 year high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the previous year, the firm earned $0.55 EPS. Insulet's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.